|Bid||10.56 x 800|
|Ask||10.58 x 800|
|Day's Range||10.42 - 10.84|
|52 Week Range||0.88 - 13.43|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.40|
The next big market for biopharma could be nonalcoholic steatohepatitis, so upcoming data from these companies could be market-moving.
NEW YORK, June 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NovoCure ...
On June 13, Viking Therapeutics (VKTX) stock rose ~9.1%, triggered by positive mid-stage trial results for peer Galmed Pharmaceuticals’ (GLMD) NASH (non-alcoholic steatohepatitis) drug, Aramchol. For more on the development, read Why Galmed Pharmaceuticals Stock Rose 151% on June 12. Galmed’s positive study results buoyed investors’ hopes of success for Viking Therapeutics’ NASH candidate, VK2809, which is in mid-stage trials and has a similar mechanism of action. On June 13, the SPDR S&P Biotech ETF (XBI) rose ~0.26%.
|Initiated||Raymond James: to Outperform||6/28/2018|
|Initiated||William Blair: to Outperform||4/30/2018|
|Initiated||Roth Capital: to Buy||11/21/2017|
|Initiated||Maxim Group: to Buy||5/24/2016|
|Initiated||H.C. Wainwright: to Buy||4/7/2016|
Full Time Employees: 11
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.